{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032189","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.633230+00:00","generated_at":"2026-05-31T09:20:08.649492+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Matinas BioPharma Q2 net loss $5.7M ($0.02/sh); signs non-binding MAT2203 term sheet","bullets":["Net loss for Q2 2024 was $5.7 million ($0.02 per share), compared to $6.1 million ($0.03) in Q2 2023.","Cash, cash equivalents and marketable securities were $14.3 million as of June 30, 2024; raised $10M in April offering.","Signed non-binding term sheet for global licensing rights to develop and commercialize oral MAT2203 for invasive aspergillosis.","31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program; 7 additional under evaluation.","LNC platform showed tumor inhibition in animal models; additional optimization needed before selecting product candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032189","json":"https://secwatch.observer/filing/0001493152-24-032189.json","markdown":"https://secwatch.observer/filing/0001493152-24-032189.md","text":"https://secwatch.observer/filing/0001493152-24-032189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224032189/0001493152-24-032189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224032189/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:20:08.649492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}